(NASDAQ: ACIU) Ac Immune Sa's forecast annual revenue growth rate of 151.48% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 100.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.5%.
Ac Immune Sa's revenue in 2025 is $5,397,530.On average, 5 Wall Street analysts forecast ACIU's revenue for 2025 to be $444,537,713, with the lowest ACIU revenue forecast at $316,402,693, and the highest ACIU revenue forecast at $635,630,411. On average, 5 Wall Street analysts forecast ACIU's revenue for 2026 to be $3,729,435,318, with the lowest ACIU revenue forecast at $494,379,208, and the highest ACIU revenue forecast at $9,534,456,162.
In 2027, ACIU is forecast to generate $9,072,564,730 in revenue, with the lowest revenue forecast at $8,157,256,939 and the highest revenue forecast at $9,938,939,069.